Earnings Feed
Start Free
TAKEDA PHARMACEUTICAL CO LTD·4

Apr 28, 6:08 AM ET

Weber Christophe Pierre 4

4 · TAKEDA PHARMACEUTICAL CO LTD · Filed Apr 28, 2026

Research Summary

AI-generated summary of this filing

Updated

Takeda (TAK) CEO Christophe Weber Receives RSU Awards

What Happened

  • Christophe Pierre Weber, President & CEO and Director of Takeda Pharmaceutical (TAK), was awarded a total of 323,248 share‑equivalent awards on April 27, 2026 (three entries: 78,900; 165,370; and 78,978 units). Each line was reported as an award/grant (code A) at $0.00 per unit. The awards consist of performance‑based restricted stock units (RSUs) and related derivative/tax‑equivalent awards that vest subject to achievement of specified performance metrics.

Key Details

  • Transaction date: 2026-04-27; filing date: 2026-04-28 (timely filing).
  • Reported consideration: $0.00 per unit; total units reported = 78,900 + 165,370 + 78,978 = 323,248.
  • Transaction codes: A = Award/Grant; one line reported as a derivative award.
  • Shares owned after the transaction: Not disclosed in the provided filing excerpt.
  • Notable footnotes from the filing:
    • F1/F3: Awards granted under a July 1, 2023 grant that vest in ordinary shares and American Depositary Shares (ADS) based on performance metrics (core revenue, core operating profit, R&D milestones); the Compensation Committee determined award amounts on April 27, 2026.
    • F2: “Includes 174,900 RSUs” that vest June 1, 2026 (125,000), June 1, 2027 (32,700) and June 1, 2028 (17,200).
    • F4: “Includes 369,378 RSUs” that vest July 1, 2026 (261,114), July 1, 2027 (72,384) and July 1, 2028 (35,850).
    • F5: Tax Obligation Awards are the economic equivalent of one Ordinary Share and, upon vesting, convert to a cash payment primarily to cover tax obligations.
  • Filing timeliness: Reported the day after the awards were determined; within typical Form 4 reporting windows.

Context

  • These are awards/RSUs (not open‑market purchases or sales). RSUs are conditional — they only convert to tradable shares or cash if vesting conditions are met, so they do not represent an immediate share sale or cash outlay by the insider.
  • One award type is a tax‑equivalent payment (F5) that will be settled in cash on vesting to cover taxes rather than delivering a share.
  • For retail investors, awards can signal executive compensation tied to performance targets but are not the same as a purchase (which some investors view as a stronger bullish signal).

Insider Transaction Report

Form 4
Period: 2026-04-27
TAKEDA PHARMACEUTICAL CO LTDTAK
Weber Christophe Pierre
DirectorPresident and CEO
Transactions
  • Award

    Ordinary Shares

    [F1][F2]
    2026-04-27+78,900→ 1,014,200 total
  • Award

    American Depositary Shares

    [F3][F4]
    2026-04-27+165,370→ 418,803 total
  • Award

    Tax Obligation Award

    [F5]
    2026-04-27+78,978→ 125,345 total
    From: 2026-06-01Exp: 2026-06-01→ Ordinary Shares (78,978 underlying)
Footnotes (5)
  • [F1]On July 1, 2023, the reporting person was granted an award of restricted stock units (RSUs), which vest in the form of ordinary shares based upon the achievement of the specified performance metrics, including core revenue, core operating profit, and important R&D milestones. On April 27, 2026 the Compensation Committee of the Board of Directors determined the number of RSUs to be awarded based on these performance metrics, which amount is reported above.
  • [F2]Includes 174,900 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest on the following schedule: June 1, 2026 (125,000 shares), June 1, 2027 (32,700 shares) and June 1, 2028 (17,200 shares).
  • [F3]On July 1, 2023, the reporting person was granted an award of restricted stock units (RSUs), which vest in the form of American Depositary Shares based upon the achievement of the specified performance metrics, including core revenue, core operating profit, and important R&D milestones. On April 27, 2026, the Compensation Committee of the Board of Directors determined the number of RSUs to be awarded based on these performance metrics, which amount is reported above.
  • [F4]Includes 369,378 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (261,114 shares), July 1, 2027 (72,384 shares) and July 1, 2028 (35,850 shares).
  • [F5]Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.
Signature
/s/ Max Heuer, by power of attorney, for Christophe Weber|2026-04-27

Documents

1 file
  • 4
    wk-form4_1777370932.xmlPrimary

    FORM 4